Clinical impact of c-Met expression and its gene amplification in hepatocellular carcinoma

International Journal of Clinical Oncology

Volumn 18, Issue 2, 2013, Pages 207-213

  Kondo, Shunsuke ^a   Ojima, Hidenori ^b   Tsuda, Hitoshi ^a   Hashimoto, Jun ^a   Morizane, Chigusa ^a   Ikeda, Masafumi ^c   Ueno, Hideki ^a   Tamura, Kenji ^a   Shimada, Kazuaki ^a   Kanai, Yae ^b   Okusaka, Takuji ^a  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^c NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

Author keywords

Amplification; c Met; Hepatocellular carcinoma; Recurrence

Indexed keywords

SCATTER FACTOR RECEPTOR; TUMOR MARKER;

ADULT; AGED; ANEUPLOIDY; ARTICLE; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CHROMOSOME 7; CONTROLLED STUDY; DISOMY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE EXPRESSION; GENETIC ASSOCIATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MONOSOMY; NUMERICAL CHROMOSOME ABERRATION; ONCOGENE; ONCOGENE C MET; OVERALL SURVIVAL; POLYSOMY; PORTAL VEIN; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECURRENCE FREE SURVIVAL; SURVIVAL PREDICTION; SURVIVAL RATE; SURVIVAL TIME; TUMOR INVASION; TUMOR VOLUME;

AGED; CARCINOMA, HEPATOCELLULAR; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-MET; TUMOR MARKERS, BIOLOGICAL;

EID: 84880917333     PISSN: 13419625     EISSN: 14377772     Source Type: Journal    
DOI: 10.1007/s10147-011-0361-9     Document Type: Article

References (25)

1. Parkin DM, Bray F, Ferlay J et al (2005) Global cancer statistics, 2002. CA Cancer J Clin 55:74-108
2. Donato F, Boffetta P, Puoti M (1998) A meta-analysis of epidemiological studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma. Int J Cancer 75:347-354
3. Furge KA, Zhang YW, Vande Woude GF (2000) Met receptor tyrosine kinase: enhanced signaling through adapter proteins. Oncogene 19:5582-5589
4. Kaposi-Novak P, Lee JS, Gomez-Quiroz L et al (2006) Met-regulated expression signature defines a subset of human hepatocellular carcinomas with poor prognosis and aggressive phenotype. J Clin Invest 116:1582-1595
5. Okuda K, Ohtsuki T, Obata H et al (1985) Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer 56:918-928
6. Chevret S, Trinchet JC, Mathieu D et al (1999) A new prognostic classification for predicting survival in patients with hepatocellular carcinoma. Groupe d'Etude et de Traitement du Carcinome Hepatocellulaire. J Hepatol 31:133-141
7. Iizuka N, Oka M, Yamada-Okabe H et al (2003) Oligonucleotide microarray for prediction of early intrahepatic recurrence of hepatocellular carcinoma after curative resection. Lancet 361:923-929
8. Yoshioka S, Takemasa I, Nagano H et al (2009) Molecular prediction of early recurrence after resection of hepatocellular carcinoma. Eur J Cancer 45:881-889
9. Miyamoto M, Ojima H, Iwasaki M et al (2011) Prognostic significance of overexpression of c-Met oncoprotein in cholangiocarcinoma. Br J Cancer 105:131-138
10. Cappuzzo F, Janne PA, Skokan M et al (2009) MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients. Ann Oncol 20:298-304
11. Birchmeier C, Birchmeier W, Gherardi E et al (2003) Met, metastasis, motility and more. Nat Rev Mol Cell Biol 4:915-925
12. Liu X, Yao W, Newton RC et al (2008) Targeting the c-MET signaling pathway for cancer therapy. Expert Opin Investig Drugs 17:997-1011
13. Comoglio PM, Giordano S, Trusolino L (2008) Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nat Rev Drug Discov 7:504-516
14. Ueki T, Fujimoto J, Suzuki T et al (1997) Expression of hepatocyte growth factor and its receptor, the c-met proto-oncogene, in hepatocellular carcinoma. Hepatology 25:619-623
15. Ke AW, Shi GM, Zhou J et al (2009) Role of overexpression of CD151 and/or c-Met in predicting prognosis of hepatocellular carcinoma. Hepatology 49:491-503
16. Nakajima M, Sawada H, Yamada Y et al (1999) The prognostic significance of amplification and overexpression of c-met and c-erb B-2 in human gastric carcinomas. Cancer 85:1894-1902
17. Di Renzo MF, Olivero M, Giacomini A et al (1995) Overexpression and amplification of the met/HGF receptor gene during the progression of colorectal cancer. Clin Cancer Res 1:147-154
18. Cappuzzo F, Marchetti A, Skokan M et al (2009) Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients. J Clin Oncol 27:1667-1674
19. Engelman JA, Zejnullahu K, Mitsudomi T et al (2007) MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316:1039-1043
20. Boix L, Rosa JL, Ventura F et al (1994) c-met mRNA overexpression in human hepatocellular carcinoma. Hepatology 19:88-91
21. Schmidt L, Duh FM, Chen F et al (1997) Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet 16:68-73
22. Schmidt L, Junker K, Nakaigawa N et al (1999) Novel mutations of the MET proto-oncogene in papillary renal carcinomas. Oncogene 18:2343-2350
23. Park WS, Dong SM, Kim SY et al (1999) Somatic mutations in the kinase domain of the Met/hepatocyte growth factor receptor gene in childhood hepatocellular carcinomas. Cancer Res 59:307-310
24. Di Renzo MF, Olivero M, Martone T et al (2000) Somatic mutations of the MET oncogene are selected during metastatic spread of human HNSC carcinomas. Oncogene 19:1547-1555
25. Krishnamurti U, Hammers JL, Atem FD et al (2009) Poor prognostic significance of unamplified chromosome 17 polysomy in invasive breast carcinoma. Mod Pathol 22:1044-1048